

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in this application:

Claims 1-10 (cancelled).

Claim 11 (currently amended). An aptamer comprising a first sequence capable of binding to a first target and a second sequence capable of binding to a second target, wherein said second sequence is an immunostimulatory CpG motif that stimulates an immune response, wherein said CpG motif comprises the formula: rCGyy, where "r" is a purine, "C" is cytosine, "G" is guanosine and "y" is a pyrimidine~~The aptamer of claim 3, and~~ wherein the first sequence is capable of binding to a first target selected from the group consisting of PDGF, IgE, IgE Fcε R1, prostate-specific membrane antigen (PSMA), CD22, TNF-alpha, CTLA4, PD-1, PD-L1, PD-L2, FcRIIB, BTLA, transmembrane protein containing immunoglobulin and mucin-like domains (TIM-3), CD11c, B lymphocyte activating factor (BAFF), B7-X, CD19, CD20, CD25 and CD33.

Claims 12-13 (cancelled).

Claim 14 (currently amended). A composition comprising an aptamer according to ~~any~~ ~~of claims 3, 7 and 11~~, a cytotoxic agent and a pharmaceutically acceptable carrier.

Claim 15 (original). The composition of claim 14, wherein the cytotoxic agent belongs to a class of cytotoxic agents selected from the group consisting of tubulin stabilizers, tubulin

destabilizers, anti-metabolites, purine synthesis inhibitors, nucleoside analogs, DNA alkylating agents, DNA modifying agents, and vascular disrupting agents.

Claim 16 (original). The composition of claim 14, wherein the cytotoxic agent is used alone or in combinations of one or more cytotoxic agents selected from the group consisting of calicheamycin, doxorubicin, taxol, methotrexate, gemcitabine, cytarabine, vinblastin, daunorubicin, docetaxel, irinotecan, epothilone B, epothilone D, cisplatin, carboplatin, and 5-fluoro-U.

Claims 17-64 (cancelled).